The median progression free survival was 5.6 months on sorafenib vs. 16.8 months on S+C / T ( p = 0.012 ) and there was no significant difference of overall survival between two arms ( p = 0.974 ) with median overall survival 25.6 months under sorafenib vs. 25.9 months on S+C / T. Patients remained on trial for a median of 7.8 cycles on sorafenib and 5.4 cycles on S+C / T.